Abstract
ABSTRACT The impact of the LOXL2 enzyme on cell invasion and metastasis is significantly notable in breast cancer (BC), making it a promising therapeutic target in cancer drug discovery. Considering the diverse functions of lysyl oxidase both extracellularly and intracellularly, inhibiting LOX activity emerges as a strategic approach to impede cancer progression and invasion. This study is uniquely designed to identify potential small molecules targeting LOXL2 in BC. Initially, we designed small molecuels and conducted docking studies using ChemDraw and AutoDock Vina, respectively. Assessment of ADME, drug-likeness and toxicological properties was carried out using online tools such as SwissADME, admetSAR, pkCSM and ProTox-II. The best docked candidates underwent further evaluation through 100 ns molecular dynamics simulations. Compound H.2.9 scored of −8.4 kcal/mol in docking, surpassing the control's (US10717733) −5.0 kcal/mol, indicating its potential as an LOXL2 inhibitor. ADME predictions indicated that all screened compounds adhere to Lipinski's rule of five. Additionally, toxicological predictions confirmed that these compounds are non-cytotoxic, non-hepatotoxic and non-carcinogenic. The RMSD, RMSF and MM-GBSA analyses affirmed the stability of the H.2.9 compound. The development of LOXL2 inhibitors instils optimism for effective therapies against both primary and metastatic cancers in the foreseeable future, contributing to advancements in cancer research. Abbreviations: 2D, Two-dimensional; 3D, Three-dimensional; ADMET, Absorption, distribution, metabolism, excretion and toxicity; CADD, Computer-aided drug design; MD, Molecular dynamics; MMFF, Merck molecular force field; MOL, Molecular structure file; PDB, Protein data bank; PK, Pharmacokinetics; OPLS, Optimised potentials for liquid simulations; RMSD, Root mean square deviation; RMSF, Root mean square fluctuation; SASA, Solvent-accessible surface area; SDF, Structure data file; SMILES, Simplified molecular input line entry system; SPC, Simple-point charge
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
